Why Abaloparatide May Build Bone With Fewer Side Effects Than Teriparatide: A Receptor Binding Study
Abaloparatide binds the PTH receptor in a way that produces shorter-lived signaling, which may explain why it stimulates bone formation with less bone resorption and fewer calcium spikes than teriparatide.
Quick Facts
What This Study Found
Abaloparatide (a synthetic analog of PTHrP) binds more selectively to the RG conformation of the PTH type 1 receptor (PTHR1) compared to the R0 conformation, while PTH(1-34) (teriparatide) binds both conformations more equally.
This RG-selective binding produces more transient cAMP signaling responses in PTHR1-expressing cells. Because transient (intermittent-like) receptor activation favors bone formation over bone resorption, this receptor selectivity provides a molecular explanation for why abaloparatide may build bone with less accompanying bone loss and fewer hypercalcemic side effects than teriparatide.
Key Numbers
RG vs R0 conformation selectivity · more transient cAMP responses · in vitro HEK293 cells
How They Did This
The researchers used HEK293 cells engineered to express the PTH type 1 receptor (PTHR1) and performed binding assays to measure how abaloparatide and PTH(1-34) interact with two different receptor conformations (R0 and RG). They then measured downstream cAMP signaling responses to determine whether each peptide produced sustained or transient cellular activation.
Why This Research Matters
Osteoporosis treatments that stimulate bone formation are powerful but come with trade-offs — teriparatide (PTH 1-34) can also increase bone resorption and raise calcium levels. This study reveals the molecular reason why abaloparatide may have a better safety profile: it activates the receptor in a more transient way that preferentially drives bone building. Understanding this mechanism helps explain clinical differences between the two drugs and could guide the design of even better bone-building peptides in the future.
The Bigger Picture
This study contributes to the growing understanding of how different peptides can activate the same receptor in fundamentally different ways — a concept called biased signaling. For osteoporosis, this means drugs can be designed to favor bone formation while minimizing the bone resorption that limits older therapies. Abaloparatide (marketed as Tymlos) was approved by the FDA in 2017 for osteoporosis, and this receptor-level mechanism is part of the scientific foundation supporting its development.
What This Study Doesn't Tell Us
This is an in vitro study using engineered cell lines, not human bone tissue or animal models. The receptor binding and signaling results may not directly translate to the complexity of bone biology in living organisms. The study does not include clinical outcomes or patient data.
Questions This Raises
- ?Could even more RG-selective peptide analogs be designed to further improve the bone formation-to-resorption ratio?
- ?Does this receptor binding difference fully explain the clinical differences between abaloparatide and teriparatide, or are other mechanisms involved?
- ?How does this RG-selective binding pattern translate to bone cell responses in living tissue rather than engineered cell lines?
Trust & Context
- Key Stat:
- RG-selective binding Abaloparatide preferentially binds the RG receptor conformation, producing shorter signaling bursts that favor bone building over bone breakdown
- Evidence Grade:
- This is rated Preliminary because it is an in vitro mechanistic study using engineered cell lines. While it provides an important molecular explanation, it does not include animal or human clinical data to confirm these receptor-level findings translate to actual bone outcomes.
- Study Age:
- Published in 2016, this foundational mechanistic study preceded abaloparatide's FDA approval in 2017 and remains relevant as the key explanation for its receptor pharmacology.
- Original Title:
- Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.
- Published In:
- Endocrinology, 157(1), 141-9 (2016)
- Database ID:
- RPEP-02960
Evidence Hierarchy
Frequently Asked Questions
What is the difference between the R0 and RG receptor conformations?
The PTH type 1 receptor exists in two main high-affinity shapes. The R0 conformation leads to longer-lasting signaling when activated, while the RG conformation produces briefer signaling bursts. Drugs that preferentially bind RG (like abaloparatide) create more intermittent-like activation, which favors bone building.
Does this mean abaloparatide is better than teriparatide for osteoporosis?
This study explains a molecular mechanism that may give abaloparatide advantages in terms of fewer side effects like high calcium and potentially less bone resorption. However, both drugs are effective for osteoporosis, and clinical choice depends on many factors including patient history and tolerance.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-02960APA
Hattersley, Gary; Dean, Thomas; Corbin, Braden A; Bahar, Hila; Gardella, Thomas J. (2016). Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.. Endocrinology, 157(1), 141-9. https://doi.org/10.1210/en.2015-1726
MLA
Hattersley, Gary, et al. "Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.." Endocrinology, 2016. https://doi.org/10.1210/en.2015-1726
RethinkPeptides
RethinkPeptides Research Database. "Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor..." RPEP-02960. Retrieved from https://rethinkpeptides.com/research/hattersley-2016-binding-selectivity-of-abaloparatide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.